PRMT9

Across TCGA pan-cancer cohorts, PRMT9 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PRMT9 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRMT9 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PRMT9 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, UCEC, and LUAD are the cancer types where PRMT9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.923	0.785	.011	34	view →
UCEC	DFS	Median	II,III,IV	0.553	0.872	.044	4	view →
LUAD	DFS	Median	All	0.918	0.668	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PRMT9–HNSC (OS)

Open the HNSC breakdown →